Accelerating Discovery and Manufacturing of Cell Therapies
THE IDEA
Kytopen, an MIT spin-out, is a transformative biotechnology company that offers a customizable yet scalable multi-solution platform, which seamlessly links the discovery, development and manufacturing phases of cell engineering
THE TECHNOLOGY
Flowfect®, a gentle, non-viral delivery method unlocks new therapeutic approaches, by engineering immune cells with minimal disruption, preserving the functionality and viability of human cells and enhancing the cell’s biology. The Flowfect® platform accelerates therapies from the bench to clinical through flexibility and scalability, which drives higher cell yields, faster approvals, and better outcomes from potentially curative cell-based treatments. Kytopen’s goal is to enable simple and efficient non-viral manufacturing of cell therapies in days versus weeks to increase access to many more patients